ERBB2 and prostate cancer: Previous studies show nuclear Kaiso enrichment in aggressive prostate cancers, where its inhibition reduced invasion and metastasis 28, 41, as well as in breast cancers, particularly HER2-driven and triple-negative subtypes 42.